What Are Common GMP Risks in Non-Sterile Pharmaceutical Manufacturing?

Common GMP risks in non-sterile pharmaceutical manufacturing include cross-contamination between products, inadequate cleaning validation, poor environmental and utility control, data integrity gaps, and weak change control. Non-sterile does not mean low risk. Oral solid dose, liquids, creams and APIs still carry real contamination and quality risks that regulators such as the FDA, MHRA, HPRA and EMA examine closely.

The main GMP risks in non-sterile manufacturing

The most significant GMP risks cluster around a few areas:

• Contamination that crosses between products.

• Cleaning that is not properly validated.

• Utilities that are not adequately controlled.

• Records that cannot be fully trusted.

Each is examined below.

Cross-contamination between products

Shared equipment, shared air handling and shared personnel can carry residues or actives from one product to another. In non-sterile facilities running multiple products, cross-contamination is one of the most cited GMP risks, and controlling it depends on validated cleaning, segregation and a documented risk assessment.

Inadequate cleaning validation

Cleaning that is performed but not properly validated is a frequent finding. Without validated agents, contact times and analytical limits based on health-based exposure, a site cannot prove that carryover is controlled to a safe level.

Environmental, HVAC and utility control

Non-sterile areas still rely on controlled air, water and utilities. Weak HVAC control, unmonitored water systems, or poorly maintained utilities introduce microbial and particulate risk that undermines product quality even without a sterility requirement.

Data integrity and change control

Incomplete records, unreviewed audit trails and uncontrolled changes are systemic GMP risks in any facility. In non-sterile manufacturing they often surface where manual steps and legacy equipment meet, and they erode confidence in every other control.

Frequently asked questions

Is non-sterile manufacturing lower risk than sterile?

It carries different risks, not lower ones. Cross-contamination, cleaning validation and data integrity remain significant, and regulators inspect non-sterile sites to the same GMP principles.

What is the biggest GMP risk in non-sterile manufacturing?

Cross-contamination between products on shared equipment or facilities is among the most common and most cited, which is why validated cleaning and segregation matter so much.

Does Annex 1 apply to non-sterile manufacturing?

Annex 1 formally governs sterile products, but its risk-based and contamination control principles are increasingly applied to non-sterile and API sites.

About the author

Kieran Falvey is Founder and Managing Director of Pharmalliance Consulting Ltd and the creator of Contamination Control by Design (CCbD). He has more than 20 years designing, building and running pharmaceutical facilities worldwide, across FDA, EMA, TGA, PIC/S and Indian FDA (CDSCO) jurisdictions. Global expert in cGMP Compliance, Remediation and Contamination Control, helping Sterile, Non-Sterile, ATMP and Cosmetic companies navigate cGMP compliance issues.

About Pharmalliance Consulting

Pharmalliance Consulting is a GMP compliance consultancy serving pharmaceutical, sterile, non-sterile, OSD, ATMP and cosmetic manufacturers in Ireland, the UK, the EU and the US. It helps sites identify and remediate GMP risks across facilities, quality systems and contamination control, aligned with HPRA, MHRA, EMA and FDA expectations, turning findings into defensible, inspection-ready practice.

Want to reduce GMP risk in your non-sterile operation? Explore our GMP Risk and Due Diligence and Contamination Prevention services, or contact the team.